A novel infusible botanically-derived drug, PG2, for cancer-related fatigue: A phase II double-blind, randomized placebo-controlled study Abstract Purpose: is study investigated the e cacy of the botanical-derived drug, PG2, a partially puri ed extract of Astragalus membranaceus, as a complementary and palliative medicine for managing cancer-related fatigue (CRF).
Cancer treatment is directed toward both curing and caring. In advanced cancer patients with poor disease control, palliative care to relieve symptoms causing su ering is crucial in holistic medicine management planning. Of the symptoms from which advanced cancer patients su er, cancer-related fatigue (CRF) [1] is one of the most common and di cult-to-treat symptoms. Approximately 60 to 90% of advanced cancer patients report fatigue as their most frequent and debilitating symptom [2, 3] . Fatigue can adversely a ect psychosocial and physical functioning and noticeably decrease quality of life in cancer patients [4] . Current approaches for managing CRF are unsatisfactory [5] and the development of novel and e ective treatments for improving CRF is urgently required.
Patients in need of improvement of cancer-related symptoms, including CRF, commonly use complementary and alternative medicine (CAM) by choice or because caregivers have recommended it. Traditional Chinese medicine (TCM), an important aspect of CAM, has been used for centuries. In TCM, Astragalus membranaceus is commonly used to treat the de ciency of qi (vital energy), which manifests as fatigue, diarrhea and lack of appetite [6] . Studies have shown that Astragalus membranaceus-based Chinese herbal remedies improve quality of life, alleviate chemotherapy toxicity, and boost immune functions in cancer patients [7] [8] [9] . PG2, extracted from Astragalus, has been developed as a novel CAM for cancer patients. Preclinical studies have shown that PG2 stimulates the secretion of hematopoietic growth factors from activated human peripheral blood mononuclear cells [10] , enhances the proliferation and maturation of the progenitors of peripheral blood cells in mitomycin C-treated mice [11] , and supports hematopoiesis in long-term bone marrow cultures [12] . In summary, PG2 is capable of stimulating immunity and hematopoiesis, and could play a role in the management of CRF.
In this study, a double-blind, randomized, placebocontrolled trial was conducted to examine the e ects of PG2 infusion on CRF as a palliation in patients with advanced cancer.
Materials and Methods
In estigational drug e investigational drug PG2 (PhytoHealth Corp., Taiwan) was extracted from Astragalus membranaceus as previously described [10] [11] [12] . PG2 is characterized as a mixture of polysaccharides prepared in sterile powder prior to use. For administration, each vial of 500 mg of PG2 was reconstituted with 10 ml normal saline and prepared by shaking thoroughly until completely dissolved. e dissolved solution was then injected into normal saline (490 ml) and mixed well for intravenous (IV) infusion at a rate of 150 to 200 mL/h.
Patients
Inpatients and outpatients with advanced cancer who were undergoing standard palliative care at Mackay Memorial Hospital, a medical center hospital with a hospice education center in Taiwan, were recruited for the study. e inclusion criteria were as follows: patients had advanced cancer with a fatigue score of at least 4, based on the validated Taiwanese version of the Brief Fatigue Inventory-Taiwan (BFI-T) [13] and a life expectancy of at least three months. e BFI-T is a scale for measuring the severity of fatigue in cancer patients on a scale ranging from 0 to 10, with 0 indicating no fatigue and 10 indicating extreme fatigue. e BFI-T lists nine scenarios including present, usual and most severe episodes of fatigue over the last 24 h and their interference with general activity, mood, walking ability, normal work, interpersonal relations and enjoyment of life. e tabulated composite average score, as reported by the patient, represented the patient's global fatigue severity score (BFI-T score) [13] [14] . Exclusion criteria were as follows: pregnancy or breastfeeding; a Karnofsky performance status (KPS) score of less than 30%; uncontrolled systemic diseases such as active infection, severe heart disease, hypertension, or diabetes mellitus; and use of any central nervous system stimulators or standard cancer chemotherapy within the previous 30 days. is clinical trial was reviewed and approved by the Institutional Review Board of Mackay Memorial Hospital.
Study design
Patients who met the enrollment criteria and provided written informed consent were randomly assigned to one of two groups: the PG2 group or the placebo group. During the rst cycle (4 weeks total), patients in the PG2-primed group received PG2 500 mg/day three times a week, and patients in the placebo-primed group received normal saline 500 ml three times a week). During the second cycle, all patients received open-label treatment with PG2. Because this was a doubleblind study, the investigators, clinical research coordinator and participants remained blinded to the treatment assigned to the participants during the rst cycle. e investigators assigned an authorized person to prepare PG2 or placebo injections in a locked room. is person also recorded the data and maintained the secrecy of treatment allocation. e study protocol is presented in Fig. 1 . 
CRF Assessment
To evaluate the e cacy of study drug treatment, BFI-T (Supplemental Figure 1 ) was used to assess CRF before treatment (baseline) and at the end of the rst, second and fourth week of each cycle. A fatigue-improvement responder was de ned as a person with at least 10% improvement in the BFI-T score from the baseline score at any e cacy evaluation point [15] . A fatigue-improvement response rate (FIRR) was de ned as the percentage of fatigue-improvement responders in a group at each timepoint. The purpose of this study was to compare the FIRR between the two study groups at the end of the rst treatment cycle (that is, at the end of the fourth week) and the inter-cycle changes in the FIRR from the fourth week to the eighth week within each study group. e randomized patients in this study who had no major protocol violations were evaluated. Major protocol violations were de ned as receiving any prohibited treatments during the study or receiving an incomplete during the rst cycle, de ned as receiving 10 doses or fewer of study drugs. Prohibited treatment included blood transfusion, surgery, immunomodulators, medroxyprogesterone, steroids and other herbal medicines.
ese treatments made patients ineligible for the study.
Safety evaluation
Adverse events were recorded as the onset of a new adverse e ect or as an increase in the magnitude of existing adverse e ects. Adverse events were tabulated and summarized using MedDRA (version 9.1). e patients' safety pro les included data on vital signs, results of physical examinations, and laboratory data. Data on vital signs were recorded during screening and on day of PG2 infusion. Physical examinations were conducted on the same days at each e cacy evaluation point.
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In the laboratory assessments performed during screening and at the end of each treatment cycle, hematological data, including hematocrit and hemoglobin values and red blood cell (RBC), platelet, white blood cell (WBC), and di erential counts, were collected. A biochemical pro le, including serum levels of alanine transaminase, aspartate transaminase, alkaline phosphatase, blood urea nitrogen, bilirubin, albumin, total protein, creatinine, C-reactive protein and pre-albumin, was also obtained. In addition, urine was evaluated for RBC and WBC counts, protein levels and pH.
Statistical analysis
e study was set up to include at least 30 evaluable patients from each study group for the e cacy analyses. In the primary analysis, the FIRRs of the two study groups at the end of cycle 1 were compared using Pearson's chi-squared test or Fisher's exact test. Fisher's exact test was adopted if more than 20% of cells had an expected value of less than 5. If imbalances in the BFI-T score or other measurements were found at baseline, logistic regression was used to adjust these factors in the primary e cacy evaluation. At the end of cycle 2, the inter-cycle changes in the FIRR of the two study groups were evaluated using McNemar's test. Patients showing fatigue status changes from baseline were categorized into three BFI-T score levels according to the decreases in their scores, namely "Improvement of 20% or more, " "Improvement of between 10 and 20%, " and "Improvement of less than 10%." At the end of cycle 1, the distribution of changes in patients' fatigue statuses of the two groups categorized in this manner were compared. A chisquare test or Fisher's exact test was used to analyze the categorical data. Any missing data of BFI-T score changes from baseline were regarded as "Improvement of less than 10%, " and the logistic regression method was used to adjust for withdrawal in e cacy evaluation. For drug-safety evaluation, the analyzed population included patients who were administered at least one dose of the study drugs (safety dataset). All laboratory variables and vital signs were tabulated. e chi-square or t test was used to examine di erences among two groups at baseline and the end of each treatment cycle. A value of P < 0.05 was considered statistically signi cant.
Results

Patient characteristics
A er 91 patients were screened, 90 advanced cancer patients were enrolled and randomized to either the PG2-primed group (45 patients) or the placebo-primed group (45 patients). Before the rst dosage administration, 6.7% of patients (n = 6) ntory-Taiwan (B rst study drug tr BFI-T) Score: treatment day bef e evalufore study dropped out of the study: 1.1% of patients (n = 1) were unable to adequately communicate, 1.1% of patients (n = 1) died, and 4.4% of patients (n = 4) withdrew consent. By the end of the rst cycle, 4.4% of patients (n = 4) withdrew consent, 4.4% of patients (n = 4) died during the study, 3.3% of patients (n = 3) were unconscious and were thus unable to continue to participate in the study, and an additional 8.9% of patients (n = 8) were excluded from the study because of major protocol violations. During the second cycle, 2.2% of patients (n = 2) withdrew from the study, 2.2% of patients (n = 2) died, and 3.3% of patients withdrew because of disease progression (n = 1) or adverse events (n = 2). In summary, by the end of the rst cycle (4 weeks), 72.2% of patients (n = 65) continued to participate in the study, and 64.4% of patients completed the full twocycle study (n = 58) (Fig. 2) .
All baseline demographic characteristics of those patients, including age, sex, cancer type, disease status, BFI-T score and KPS were comparable, with no statistically signi cant di erences (P > 0.05). e participants were diagnosed with various types of cancer, including head and neck, respiratory, breast (female), gastrointestinal, gynecological and reproductive (male). In the PG2-primed group (n = 35), 10 patients (29%) had breast cancer, the most frequent cancer type in the group.
irty-ve participants were 64.0 years of age on average. e average Karnofsky performance score was 66.86, and the average BFI-T score was 5.34. Twenty-four patients (69%) had distant metastasis, 27 patients (77%) did not have recurrent disease, and only four patients (11%) had lost more than 5% of their body weight in the past six months. In the placeboprimed group (n = 30), eight patients had breast cancer, the most frequent cancer type in the group. irty participants were 56.9 years of age on average. e average Karnofsky performance score was 69.33, and the average BFI-T score was 6.04. Twenty patients (67%) had distant metastasis, 22 patients (73%) did not have recurrent disease, and only four patients (13%) lost more than 5% of their body weight in the past six months (Table 1) .
CRF Assessment
In the placebo-primed group, the FIRRs evaluated at the end of cycle 2 in this group increased signi cantly a er PG2 administration (P = 0.02) relative to the value at the end of cycle 1 (Fig. 3) . During cycle 1, the intergroup analysis showed that initial PG2 administration resulted in a signi cantly greater FIRR than NS infusion (FIRR 57% vs. 32% at week 1, P = 0.043 By weeks two and four, there were no signi cant di erences between the two groups ( Table 2) . In laboratory tests, only the monocyte levels were signi cantly di erent a er the 2-cycle treatment between the two groups (P = 0.021) (Table  3) . Furthermore, although a 10% improvement in the BFI-T score was required to de ne a participant as a responder, 72% (15/21) of the 60% (21/35) of those who reported an improvement in fatigue symptoms in the PG2-primed group reported greater than 20% improvement at the end of cycle 1 (Fig. 4) . In addition, approximately 82% of PG2 responders felt a sustained bene cial e ect on CRF a er the subsequent second-cycle administration. Furthermore, among the PG2 non-responders in the rst cycle infusion, 71% of patients reported improvement a er the second-cycle administration, indicating a possible positive role of prolonged administration for up to 8 weeks. A er eight weeks of treatment, 17.6% of the patients in the PG2-primed group gained over 5% of their weight before the tests. None of the patients in the placeboprimed group gained over 5% of their weight before the tests. We further analyzed the BFI-T question 4 sub-questions to explore the in uences of fatigue at di erent levels. Results show that at the end of cycle 1, the score of question 4b, which was related to emotional level, was 0.87 lower on average, which was the largest di erence from the baseline. At the end of cycle 2, the largest improvement was in question 4c, which was used to evaluate walking ability. e reduction was 1.29 on average. is was followed by question 4b, with a reduction of 1.26 on average.
Toxicity Evaluation
No evident di erence in the number and severity of adverse events between the PG2-primed and the placebo-primed groups was observed. None of the severe adverse events (SAE) was deemed to be causally related to PG2 treatment. e adverse events exclusively associated with PG2 administration were rashes (three cases), eczema (two cases), and pruritus (two cases) ( Table 4 ). Most of these adverse events were minor, and all patients recovered without medical treatment in a short time. Additionally, the laboratory pro les, physical examination results and vital signs were similar between the two study groups. 
Discussion
To our knowledge, this was the rst randomized trial to evaluate the e cacy of Astragalus membranaceus in CRF of advanced cancer patients by using a double-blind design with both placebo-controlled and self-controlled groups. A fourweek treatment cycle was used because of our clinical practices: cancer patients generally return for visits every four weeks when not undergoing any special treatment. e two-cycle design allowed patients treated with placebo the opportunity to be treated with PG2 to obtain any bene ts; however, only the data from the rst treatment cycle can be used to compare the e cacy of PG2 with the placebo, due to the study's doubleblind, randomized and placebo-controlled design. Additionally, because there were two cycles for the PG2-primed group, exploring the cumulative e ect of PG2 was possible. Our results show that PG2 administration is safe and e ective and can achieve fatigue improvement in advanced cancer patients when used over an eight-week interval. e di erence in the FIRR between the two groups was signi cant during the rst week of the rst cycle, but no signi cant di erence was seen in subsequent weeks. is may be attributed to the small number of participants enrolled in the study. Conversely, the FIRRs in the placebo-primed group increased signi cantly a er PG2 treatment during the second cycle ( Figure 3 ). is di erence in FIRRs was the most convincing and consistent nding in our study, and suggests that PG2 may improve CRF in advanced cancer patients. In cancer patients, fatigue and depression might coexist and show considerable overlap of symptoms [5, 15, 16] . e common pharmacological interventions for CRF include psychostimulants and corticosteroids. Psychostimulants show great promise in the alleviation of CRF through the psychiatric approach [15, 17] ; however, these compounds are associated with a high risk of abuse and have adverse e ects, including irritability, anorexia, insomnia, uctuations in mood, nausea and heart beat irregularities [5, 14, [16] [17] [18] . Glucocorticoids have been used in CRF treatment to relieve physical symptoms; however, recent studies show that short-term glucocorticoid administration improves CRF, whereas long-term use causes detrimental side e ects such as muscle wastage [5, 19] .
Chinese patients with advanced cancer frequently resort to TCM for general symptom relief [20] . Astragalus, with a long history of usage in TCM, has demonstrated a wide range of immunopotentiating e ects [21, 22] , has proven to stimulate cell-mediated immune mechanisms, and has e ects on cardiovascular and neuroendocrine systems. It is also e ective as an adjunct cancer therapy to prolong survival, increase tumor response, decrease chemotherapy toxicity, and improve quality of [8, 9, 23] . In a randomized controlled trial, the WBC, platelets and CD8 of the patients treated with Astragalus were reduced [8] . Compared with patients without Astragalus, the CD4/CD8 ratio, IgM, and IgG increased [8] . In some studies, Astragalus is believed to improve immune functions such as WBC and lymphocytes [8, 24] . In numerous studies on immunology and cytokines, values of WBC, lymphocytes, CD4, and CD8 are considered to be related to fatigue [25, 26] . e scienti c evidence of its e ectiveness was limited prior to our study because most studies are not double-blinded and placebocontrolled [7] [8] [9] . In this study, patients treated with PG2 reported a greater improvement in fatigue symptoms than with NS injection. Additionally, PG2 proved to be an e ective enhancement of mood and thus enjoyment of life for patients.
ese results are valuable because fatigue and depression may coexist and show considerable overlap of symptoms in cancer patients [5, 15, 16] . To our knowledge, PG2 is the rst fatigue modulator to relieve fatigue-related psychosocial distress. Moreover, the adverse events among patients receiving PG2 were not signi cantly di erent from those among patients receiving the placebo, proving minimal adverse risks related to PG2 application to patients. e high placebo e ect observed in this study has also been reported in previous studies on CRF [15, 18, 27] . Finding an appropriate placebo is o en di cult, especially in clinical trials of Chinese herbal medicine [7] , and numerous studies have demonstrated that di erent routes of placebo administration trigger di erent responses. Nevertheless, researchers believe that a placebo-controlled trial is essential to determine whether the ndings are independent or caused by an extension of the placebo e ect [5, 15, 17, 18, [28] [29] [30] . In future studies, the placebo-controlled group should be established as a baseline comparison to other non-controlled groups. For this study, we used intravenously administered normal saline (500 mg/ day, three times per week) as the placebo during the rst treatment cycle (FIRR, 29-40%). Although reports indicate that patients believe arti cial nutrition (feeding through a nasogastric or gastrostomy tube, or total parenteral nutrition) to relieve their symptoms [26] , no study has evaluated the e ect of normal saline injection for CRF; therefore, future studies can also focus on this particular area.
During the initial enrollment of participants, a range of cancer diseases were included in the study. We observed that the application of PG2 among various cancer types yielded notable variances of CRF relief. In our study, most of the participants had breast cancer (18 participants) or head and neck cancer (13 participants). In the rst treatment cycle, 70% (7/ 10) of the breast cancer patients who received PG2 treatment were fatigue-improvement responders. is percentage was the highest among all the groups with di erent types of cancers. e second highest percentage was 67% (4/6) with the head and neck cancer patients. In addition, 8 patients in the control group were fatigue-improvement non-responders in the rst cycle, but responders in the second cycle. Among them, ve were breast cancer patients, comprising 62.5% of the breast cancer patients in the control group. is means that PG2 was helpful for breast cancer patients. In future studies, focusing on the speci city of cancer types or patient sex would be bene cial to determine the maximum e ectiveness of PG2 on particular patients.
In future studies, an expansion of study cycles from two to additional cycles, possibly following patients' disease progressions until death, would be helpful. is could provide additional data to evaluate the consistency of PG2 e ectiveness on CRF, even during patients' rapid nal deterioration, thus potentially proving a greater potency of PG2 in patients with endstage cancer, even if the FIRR re ects only 10% improvement when compared to the enrollment baseline data.
e limitations of this study include a moderate dropout rate, rapid disease progression during treatment course, and moderate sample size, all of which could contribute to the only marginal improvement of FIRR. e rate of dropout might be because of the relative weakness of the enrolled participants, which compromised compliance with transporting patients to the hospital to receive drug infusions three times per week. Another limitation is the rapid disease progression and short life expectancy of far-advanced cancer patients, which leads to incomplete e cacy evaluation and withdrawal from the study. Ethical considerations suggest that expanding recruitment solely to reach a statistical di erence may be inappropriate. Nevertheless, the e cacy of PG2 could be validated by a signi cant improvement of FIRR in the placebo-primed group before and a er PG2 administration, although the compassionate design in cycle two is open-labeled.
Conclusion
PG2 could be an e ective and safe palliative treatment for relieving fatigue in advanced cancer patients.
